Fig. 1 · Structure

Documents & Downloads

(R)-Sulforaphane

Cat. No. A21690 CAS 142825-10-3

Keap1/Nrf2/ARE pathway inducer

(R)-Sulforaphane is a highly potent inducer of the Keap1/Nrf2/ARE pathway. (R)-Sulforaphane is a far more potent inducer of the carcinogen-detoxifying enzyme systems in rat liver and lung than the S-isomer.

In Stock

Publications for (R)-Sulforaphane

1 publication citing this product

  1. Isin Cakir, .et al. , Elife, 2022, Mar 24 PMID: 35323110

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In human breast-cell models, reported R-sulforaphane increased nuclear Nrf2 protein and NQO1 expression after 72 h. These expression endpoints support a cellular Nrf2-associated response; they do not establish direct KEAP1 binding or Nrf2 dependence. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 19.6 μM Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay [PMID: 25299679]
MRC5 IC50 46.58 μM Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay [PMID: 25299679]

(R)-Sulforaphane Research Summary

This section summarizes 1 in vitro study of (R)-Sulforaphane from 1 published reference.

(R)-Sulforaphane In Vitro Studies

Reported R-sulforaphane altered gene and protein expression in MCF7, MDA-MB-231 and non-tumorigenic MCF10A cells. GSTP induction occurred in the cancer-cell models but was absent in MCF10A. AhR protein decreased only in MCF7, while ERα protein remained unchanged in the tested MCF7 and MCF10A cells. The authors caution that GSTP induction may be unfavorable in a cancer context; therapeutic benefit was not tested. [1]

R-sulforaphane expression responses in three human breast-cell models

Cell-based study · ERα-positive MCF7 and ERα-negative MDA-MB-231 breast cancer cells; non-tumorigenic immortalized MCF10A breast epithelial cells. ERα expression was evaluated in MCF7 and MCF10A. [1]

A single comparative 72 h exposure design measured Nrf2, NQO1, GSTP, AhR and ERα expression. Figures report mean ± SEM from three independent experiments performed in triplicate, relative to control expression = 1. One-way ANOVA with Dunnett’s post hoc test assessed significance at p < 0.05. Gene-expression changes did not uniformly predict protein changes; functional estrogen metabolism, cancer prevention and treatment efficacy were not measured.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Nrf2 transcript and nuclear proteinRelative expression versus vehicle control Nuclear protein increased in all three cell lines; transcript responses depended on cell line and concentration. No exact fold values transcribed from bars.[1]
NQO1 transcript and proteinRelative expression versus vehicle control Increased in MCF7, MDA-MB-231 and MCF10A; largest transcript/protein response reported in MCF7.[1]
GSTP transcript and proteinRelative expression versus vehicle control Induction in breast cancer cells was concentration dependent; neither transcript nor protein was increased in MCF10A.[1]
AhR transcript and proteinRelative expression versus vehicle control MCF7: decreased transcript and protein. MDA-MB-231: increased transcript without increased protein. MCF10A: protein unchanged.[1]
ERα transcript and proteinRelative expression versus vehicle control At 20 µM, ERα transcript decreased in MCF7; ERα protein remained unchanged in MCF7 and MCF10A.[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 µM in all cell lines; additionally 20 µM in MCF7 and MDA-MB-231, or 10 µM in MCF10A.
Exposure duration
72 h exposure after a 24 h pre-incubation.
Method
Addition to cell culture; vehicle-treated cultures served as controls.
Vehicle
DMSO; vehicle controls not exceeding 0.1%.
Reported limits
R-SFN doses were selected using a cytotoxicity assay in a previous publication, which was not acquired; no viability or IC50 claim is adopted from that predecessor. Enantiomeric purity and product lot identity are not established here.
Methods and source locations

Compound reported in the paper: (R)-Sulforaphane; Compound label in the paper: R-SFN; (−)1-isothiocyanato-4R-(methylsulfinyl)-butane

Evidence concerns the authors’ reported R-SFN reagent in cultured human cells, with model-specific expression endpoints.

Materials and methods: Chemicals, Cell culture and treatment, Real-time PCR, Western blot analysis, Statistical analysis; Results; Figs. 1–4 and captions; Discussion

Nrf2 transcript and nuclear protein: RT-qPCR normalized to TBP/PBGD; immunoblotting with lamin control. — Results: The effect of R-sulforaphane on the expression of Nrf2; Fig. 2a–c; Methods: Real-time PCR and Western blot analysis

NQO1 transcript and protein: RT-qPCR and cytosolic immunoblotting with β-actin control. — Results: The effect of R-sulforaphane on the expression of phase II enzymes; Fig. 1a–c

GSTP transcript and protein: RT-qPCR and cytosolic immunoblotting with β-actin control. — Results: The effect of R-sulforaphane on the expression of phase II enzymes; Fig. 1d–f

AhR transcript and protein: RT-qPCR and whole-cell immunoblotting with β-actin control. — Results: The effect of R-sulforaphane on the expression of AhR; Fig. 3a–c

ERα transcript and protein: RT-qPCR and whole-cell immunoblotting with β-actin control. — Results: The effect of R-sulforaphane on the expression of ERα; Fig. 4a–c

Specifications

Manufacturer Adooq Bioscience
Actions Inducer
CAS Number 142825-10-3
Applications Keap1/Nrf2/ARE pathway inducer
Formula C6H11NOS2
Molecular Weight 177.29
SMILES
O=[S@@](CCCCN=C=S)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

(R)-Sulforaphane Research References

  1. [1] Barbara Licznerska, Hanna Szaefer, Violetta Krajka-Kuźniak. R-sulforaphane modulates the expression profile of AhR, ERα, Nrf2, NQO1, and GSTP in human breast cell lines Molecular and Cellular Biochemistry (2021). PMID: 33064289 DOI: 10.1007/s11010-020-03913-5 Source material

Publications

1 publication citing this product

  1. Isin Cakir, .et al. , Elife, 2022, Mar 24 PMID: 35323110

Added to your cart

View Cart Checkout
Loading...